NEWS CATEGORY : ALL News Event Press Goods/Services 2024.10.07News PharmaBio is going to set up an exhibition booth at Japan Healthcare Venture Summit 2024 organized by Ministry of Health, Labour and Welfare. 2024.01.09Press Notice regarding Joint Research Agreement on brand-new Cell Sheets 2023.12.21Goods/Services PharmaBio launches the new testing service for SARS-Cov-2! 2023.07.26Press Joint Research and Development Agreement on "Human (Allogeneic) Subcutaneous Adipose Tissue-Derived Mesenchymal Stem Cell Sheet (PAL-222) for Patients with Myopic Chorioretinal Atrophy 2023.04.26News Notice of Address Change 2023.03.15Press Notice regarding commencement of first-in-human for clinical trial of human (allogenic) subcutaneous adipose tissue derived mesenchymal stem cell sheet (PAL-222) transplantation for myopic chorioretinal atrophy – Phase 1/2a clinical trial (PAMyCA Study) 2022.12.12Press Notice regarding Joint Development of Manufacturing Equipment and Materials for “Cell Sheets” 2022.11.25News PharmaBio is going to join ILS Startup Show on December 1 and 2. 2022.10.03News (News) PharmaBio is going to set up an exhibition booth at Japan Healthcare Venture Summit 2022 organized by Ministry of Health, Labour and Welfare. 2021.02.09Press First-in-Human trial on human (autologous) iris pigment epithelial cell sheet transplantation for myopic chorioretinal atrophy has begun recruiting patients at Nagoya City University Hospital. 2020.06.17Press Notice regarding Capital Alliance between PharmaBio Corporation and Alfresa Corporation 2019.08.26News Pharmabio concluded an agreement with Janssen Pharmaceutical K. K. 2018.10.24News PharmaBio Corporation Had Ceremony to Celebrate the Completion and Preview Party of Brand-New Cell Factory 2018.04.16News Dr. Tetsuo Nagano, Professor Emeritus of Tokyo University and former Executive Director of the Pharmaceutical and Medical Device Agency (PMDA) , invited as company advisor at PharmaBio Corporation CONTACT US For more details, questions, and quotes about PharmaBio’s services, please use the email form. MAIL FORM